Company profile
Mogrify | Reprogramming Health
Mogrify is transforming the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzUxMjc3NDAyMGFkaXF6a2N4
Published 28 Mar 2026 07:26
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQzODcyOTQ4NGFkaXF6a2N4
Published 08 Oct 2024 12:08
Company registered at Companies House
Cell Mogrify is starting out as in IP based biotech company for the purpose of translating and commercialising the Mogrify work published in Nature Genetics that is also the subject of a patent application. The company aims to generate novel cell conversions and work with partner companies to make industrial use of them.
Mogrify develops software that use big data approaches for cellular reprogramming for disease areas such as ophthalmology and immuno-oncology.
The company was only formed recently and is in its infancy.
1 Jul 2019 to 31 Mar 2021
Our understanding of biology and advancements in technology are rapidly changing the way that we both diagnose and treat disease. One area where this change is being experienced is in the area of cell therapy, an area of medicine which involves treating disease by replacing or regenerating patient tissues in order to overcome disease. These tailor-made th...
